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Abstract
Background: A series of human diseases are caused by the misfolding and aggregation of specific proteins or
peptides into amyloid fibrils; nine of these diseases, referred to as polyglutamine diseases, are associated with
proteins carrying an expanded polyglutamine (polyQ) region. While the presence of this latter is thought to be the
determinant factor for the development of polyQ diseases, the non-polyQ regions of the host proteins are thought
to play a significant modulating role.
Method: In order to better understand the role of non-polyQ regions, the toxic effects of model proteins bearing
different polyQ regions (containing up to 79 residues) embedded at two distinct locations within the β-lactamase
(BlaP) host enzyme were evaluated in Caenorhabditis elegans. This small organism can be advantageous for the
validation of in vitro findings, as it provides a multicellular context yet avoids the typical complexity of common
studies relying on vertebrate models. Several phenotypic assays were performed in order to screen for potential
toxic effects of the different BlaP-polyQ proteins.
Results: Despite the significant in vitro aggregation of BlaP-polyQ proteins with long polyQ regions, none of the
BlaP-polyQ chimeras aggregated in the generated transgenic in vivo models.
Conclusion: The absence of a toxic effect of the expression of BlaP-polyQ chimeras may find its cause in
biochemical mechanisms present in vivo to cope with protein aggregation (e.g. presence of chaperones) or in C.
elegans’ limitations such as its short lifespan. It is plausible that the aggregation propensities of the different BlaP
chimeras containing embedded polyQ sequences are too low in this in vivo environment to permit their
aggregation. These experiments emphasize the need for several comparative and in vivo verification studies of
biologically relevant in vitro findings, which reveal both the strengths and limitations of widely used model
systems.
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Background
The aggregation of proteins or peptides into amyloid fibrils
is associated with a series of prevalent and intensively
studied neurodegenerative diseases. Amongst these, nine
diseases referred to as polyQ diseases - including
Huntington’s disease – all arise from an abnormal
expansion of an unstable CAG repeat in the coding region
of one of the nine associated genes [1]; these expanded
CAG repeats are translated into an extended polyglutamine
(polyQ) region within the corresponding protein. PolyQ
proteins only become pathogenic if they contain a polyQ
region longer than a threshold value, situated between 35
to 45 glutamine residues in most of the nine proteins [2].
Moreover, the age of onset of polyQ disorders is inversely
correlated with the length of the polyQ region [3], i.e. above
the pathogenic threshold, the longer the polyQ region, the
earlier the onset [4, 5]. Finally, polyQ regions longer than
the pathologic threshold induce the aggregation of the host
protein into amyloid fibrils [6, 7]. The exact mechanism of
polyQ toxicity is still unknown, but a vast amount of data
indicate that protein misfolding and aggregation into amyl-
oid fibrils underlie these processes [1, 8–10].
While the detrimental aggregation propensity of polyQ
proteins critically depends on the presence of an
extended polyQ region, the properties of the host
protein (i.e. the non-polyQ regions) can significantly
influence the kinetics of aggregation and the properties
of the aggregates formed [1, 11, 12]. Depending on the
non-polyQ regions, the aggregation into amyloid fibrils
can be favored or prevented [13–16], and the molecular
mechanisms of the complex interplay between the ability
of expanded polyQ sequences to trigger aggregation and
the modulating role of non-polyQ regions is still not
fully clarified. For example, the contributions of the
sequence, size, topology, structure, stability or dynamics
of the host protein are not yet fully addressed. Since
most proteins associated with polyQ diseases are rather
big and exhibit limited solubility when containing long
polyQ sequences [1, 12, 15], a number of artificial model
polyQ proteins (i.e. comprising a host protein not
associated with any polyQ disease and a polyQ region of
different lengths) have been engineered in order to ad-
dress these unanswered questions [6]. One of these relies
on the use of the β-lactamase BlaP (30.4 kDa) from Ba-
cillus licheniformis 749/C as host protein [6, 17]. This
two-domain host protein (Fig. 1) has been chosen
because its thermodynamic and catalytic properties are
well known, providing a strong basis to investigate the
effects of polyQ insertion [12] but most importantly be-
cause two distinct positions (so-called sites 197 and 216,
see Fig.1) within the protein have been shown to tolerate
amino acid insertions [6, 17]. BlaP is the only host pro-
tein that can be produced recombinantly in which long
polyQ regions have been successfully inserted at two
different locations and whose in vitro properties could
be extensively investigated; this is instrumental in
assessing how subtle differences between polyQ region
insertional environments - without disturbing the overall
protein structure - affect the ability of polyQ sequences
to trigger aggregation [18]. The aggregation properties
of two sets of BlaP-polyQ chimeras with polyQ
insertions at either position 197 or 216 recapitulate
those of polyQ proteins associated with diseases: there is
a threshold polyQ length above which the chimeras form
in vitro amyloid fibrils and above the threshold, the
longer the polyQ, the faster the aggregation [6, 18].
Moreover, BlaP chimeras bearing a polyQ region at
position 216 have a significantly higher aggregation
propensity than their counterparts with polyQ insertions
at position 197: the polyQ length threshold for fibril
formation is lower and above this threshold, chimeras
with insertions at position 216 aggregate faster than
chimeras with polyQ insertions of similar length at
position 197 [6, 18]. This could be because the 197
insertion site is located within the folded α-domain of
BlaP, in contrast to the 216 insertion site, which is
located at the interface of the α-domain and the α/β-do-
main. This interdomain insertion is thought to
destabilize the interface between the domains and could
therefore result in a higher aggregation propensity of
BlaP216 chimeras. These results highlight the critical
role of subtle modifications in the properties of the non-
polyQ region on the in vitro aggregation properties of
polyQ proteins.
Fig. 1 X-ray crystal structure of the β-lactamase from Bacillus licheniformis
749/C. The α- and α/β-domains are represented in light blue and light
green, respectively. The two insertion sites 197 (located between helices
8 and 9) and 216 (inserted between helices 9 and 10) are coloured in red
and are highlighted by two red arrows. The serine active site is repre-
sented by a sphere in dark blue. The numbering of the insertion sites, i.e.,
positions 197 and 216, refers to the numbering scheme of class A β-
lactamases [74], which correspond to residues 168 and 187 in the se-
quence of the protein [74]
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While artificial proteins with expanded polyQ repeats
have been shown to display robust aggregation in vitro,
the in vivo effects are unknown. Thus, this study aimed
to address this point and to investigate the consequences
of subtle differences between polyQ region insertional
environments within the same host protein on the in
vivo consequences for polyQ protein aggregation. For
this, various BlaP-polyQ proteins were expressed in the
nematode Caenorhabditis elegans. This relatively simple
organism was chosen because it has become a popular
model for studying development, aging, neurobiology
and protein aggregation, amongst others [19, 20]. Its
transparency, fast reproduction, short lifespan, easy
phenotyping, powerful genetic toolbox and fully
sequenced genome are some of its widely appreciated
advantages [21]. Additionally, in C. elegans, evidence has
been gathered showing that protein quality control
processes and protein degradation pathways influence
toxic protein aggregation [22, 23]. Many protein-
misfolding disorders have already been modelled with
success in this animal, as supported by the availability of
diverse amyloid-β, tau, superoxide dismutase and polyQ
expressing strains [24–27]. This nematode has also
proved its worth in compound screens against toxic
protein aggregates [28].
Specifically with regards to modelling polyQ disorders,
several efforts relying on C. elegans as an in vivo context
have already been made. Most of these models exhibit a
C-terminal polyQ region. For instance, muscle-specific
expression of terminal polyQ regions fused to only 17
amino acids from the dentatorubural pallidoluysian
atrophy protein were employed to study the protective
effects of C. elegans p97 homologs [29]. In addition,
several models rely on fusions of polyQ regions with
fluorescent proteins, allowing direct observation of in
vivo aggregation thanks to C. elegans’ transparency.
While neuronal expression of such proteins certainly has
been used (e.g. [25]), body wall muscle expression of
polyQ fusion proteins is popular in C. elegans [30–32],
the latter having the advantage of mobility impairment
as an easy readout. These studies also allowed the
identification of several genes whose reduced expression
enhanced the observed aggregation, and contributed to
our understanding of the role of protein homeostasis in
polyQ diseases.
Also in C. elegans, a number of studies to date have
already focused on the effect of polyQ regions embedded
within the host protein. For example, several studies
based on N-terminal fragments of huntingtin delivered
insights into the correlation between polyQ region
length and the severity of the observed defects in C.
elegans [33], neuronal toxicity of [34], and ubiquilin
protection against [35] polyQ-containing huntingtin
fragments, and the age-associated remodelling of
neurons [36]. In another study using polyQ regions
longer than 60 repeats and embedded within ataxin-3,
an imbalance in cellular aggregation-associated proteo-
toxicity was observed [37].
In general, phenotypic readouts are observed for polyQ
regions longer than a certain threshold length, however,
its value varies significantly (from 40 Q to >120 Q) over
different studies. This observation holds true in worms,
yeast, flies and mice [34, 38]; and the observed threshold
is often larger than that observed in human diseases [34].
Knowing this, it is however difficult to draw any conclu-
sions regarding the specific role of the non-polyQ regions,
which differ between these studies, since many other
parameters – such as the spatiotemporal expression or the
age of the animals – vary over studies as well. Still, there is
evidence to clearly identify the non-polyQ regions as
modulators of in vivo polyQ aggregation. For example,
full-length and truncated human ataxin-3, both containing
polyQ regions of various sizes were expressed in the
nervous system of C. elegans, which showed that the trun-
cated version of the protein aggregates faster than the full
length protein [39]. Another study relied on transient
cellular expression of GFP fusion proteins containing
56 Qs and a fixed number of flanking amino acids (8 N-
terminal and 9 C-terminal). These sequences were identi-
cal to those known to also flank the polyQ region in vari-
ous proteins associated with polyQ diseases, and the study
showed that these significantly modulate the aggregating
properties of the polyQ-GFP fusion proteins [40].
In line with these studies, our work aimed to expand
on the knowledge regarding in vivo effects of protein
context. By expressing, in C. elegans, various BlaP-polyQ
chimeras in which a polyQ region is inserted at different
locations, we aimed to evaluate whether the observed
effects of the location of the polyQ insertion on the in
vitro aggregating properties would also be observed in
vivo; or in other words whether the in vivo aggregation
would be as sensible to subtle changes in the polyQ
environment as the in vitro aggregation is.
Methods
Strains and culturing
Strains (N2 wild type, SJ17 (xbp-1(zc12)) III, CL4176
dvIs27 [pAF29 (Pmyo-3::Aβ(1-42)::let-383 3’UTR) + pRF4
(rol-6(su1006))] X, CL2120 dvIs14 [pCL26 (Punc-54/
Aβ1-42) + pCL12 (mtl-2::GFP)], AM 140 rmIs132
[Punc-54::Q35::YFP]) used in this article were obtained
from the Caenorhabditis Genetics Center (CGC) (Uni-
versity of Minnesota). Plasmids for Punc54::Q82::YFP,
PF25B3.3::Q0::CFP and PF25B3.3::Q86::CFP expression
were a kind gift of the Morimoto lab [32, 41]. Strains
were cultured on standard nematode growth medium
(NGM) seeded with Escherichia coli OP50 [42] and all
experiments were conducted at 20 °C. To generate age-
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synchronized worm populations, adult animals were trans-
ferred to fresh NGM plates, allowed to lay eggs for 2 h and
thereafter removed. The offspring was then used in the
experiment.
Construction of transgenic C. elegans strains expressing
BlaP-polyQ chimeras
A series of transgenic C. elegans expressing different BlaP-
polyQ chimeras (BlaP197Q0, BlaP197Q58, BlaP197Q72,
BlaP216Q0, BlaP216Q55, BlaP216Q79, under the control
of different promoters were created (Table 1). All of the
BlaP-polyQ chimeras were expressed under the control of
the body wall muscle-specific unc-54 promoter.
BlaP216Q0, BlaP216Q55 and BlaP216Q79 were addition-
ally expressed under control of the constitutive and
ubiquitous rpl-28 promoter. BlaP197Q72 was also
expressed in an AM140 background, expressing Q35::YFP
in body wall muscle cells. BlaP197Q0 and BlaP216Q0
refer to BlaP chimeras where a PG dipeptide has been
introduced at position 197 and 216. This di-peptide
originates from the addition of the SmaI restriction site at
the genetic level to allow further polyQ region insertion [6].
Sequences coding for the BlaP chimeras with
insertions at position 197 (i.e. BlaP197 chimeras) were
amplified from plasmid pNY (i.e. from pNY-BlaP197Q0,
pNY-BlaP197Q55 and pNY-BlaP197Q79, [7]) using 5′-
ACACACGCTAGCACGGAGATGAAAGATGATTT-3′
and 5′- CTGCTGTAGCTCGTGGTGGTGGTGGTG
GGGCCCT-3′ primers. These sequences were inserted
between unique NheI and SacI sites of the pPD30.38
vector (Addgene). Sequences coding for the BlaP
chimeras with insertions at position 216 (i.e. BlaP216
chimeras) were inserted in pPD30.38 and L4455 vectors at
the unique SacI site using Gibson Assembly® Master Mix
(New England Biolabs). Sequences coding for these
chimeras were amplified from a pET28b (pET28b-
BlaP216Q0, pET28b-BlaP216Q55 and pET28b-
BlaP216Q79), vector template using 5′- ATGGTATTGAT
ATCTGAGCTATGAAAGATGATTTTGCTAAACTG-3′
and 5′- ATGACAGCGGCCGATGCGGAGCTTTTCC
ACGTACGTTG-3′ primers for later insertion into
pPD30.38, and 5′- AAATATCCGACGCTCTCGTGATG
AAAGATGATTTTGCTAAACTG-3′ and 5′-
ATTTTTTCTGAGCCAATCCCGGGTTTCCACGTACG
ACGTTG-3′ primers for later insertion into L4455.
For the BlaP197 chimera the sequencing revealed that
the polyQ region had a length slightly different than in
the parent vector (i.e. 58Q instead of 55Q, and 72Q in-
stead of 79Q). Therefore, these two chimeric proteins do
contain a polyQ region whose length is slightly different
than that of the proteins used to study in vitro aggrega-
tion [6, 18].
All constructs were microinjected at high concentration
(70 ng/μl) into the gonads of young adults, together with
co-injection marker Pelt-2::gfp (50 ng/μl) and 1 kb generu-
ler DNA ladder (Thermo Scientific) as carrier DNA
(17 ng/μl). An extrachromosomal array is formed and is
transmitted to the offspring, eventually generating mul-
tiple stable transgenic strains.
Western blot analysis
The expression of BlaP chimeras by the worms was inves-
tigated by Western blot analysis under denaturing condi-
tions. 50 synchronized adult worms were picked in 30 μl
S-buffer [42]. Subsequently, worms were centrifuged (800
x g, 3 min, 4 °C) and 15 μl buffer were removed. Next,
15 μl of 2-mercaptoethanol enriched Laemmli buffer (2×)
(1,610,737, BioRad) were added to the worm pellet and
the samples were incubated for 15 min at 70 °C; during
this process, the samples were vortexed every 5 min. Sam-
ples were stored at −80 °C until further use.
Proteins were separated on a precast SDS/PAGE gel
(4-12% Midi gels, Biorad), for this purpose 15 μl of each
sample were loaded on the gel. After separation, the
proteins were blotted on a polyvinylidene difluoride
membrane (Biorad) and a coomassie-based total protein
Table 1 List of generated transgenic strains
Promoter Background strain Location of polyQ insertion PolyQ length Protein name
Body wall muscle cells N2 197 0 BlaP197Q0
Body wall muscle cells N2 197 58 BlaP197Q58
Body wall muscle cells N2 197 72 BlaP197Q72
Body wall muscle cells N2 216 0 BlaP216Q0
Body wall muscle cells N2 216 55 BlaP216Q55
Body wall muscle cells N2 216 79 BlaP216Q79
Ubiquitous N2 216 0 BlaP216Q0
Ubiquitous N2 216 55 BlaP216Q55
Ubiquitous N2 216 79 BlaP216Q79
Body wall muscle cells AM140 197 72 BlaP197Q72
Promoter, background strain, location of insertion, length of polyQ region and protein name are indicated
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stain was performed (Additional file 1: Figure S1). A
blocking step (2 h) was conducted using 5% blocking
agent (GE Healthcare). The membrane was incubated
overnight at room temperature with primary mouse
anti-polyQ antibody (1/1000 dilution in Tris-Saline
pH 7.6, 5TF1-1C2, Millipore) or primary rabbit anti-
GFP antibody (1/1000 dilution in Tris-Saline pH 7.6,
ab6556, Abcam). Horse Radish Peroxidase-conjugated
rabbit anti-mouse (1/50000 dilution in Tris-Saline
pH 7.6, P0161, Dako) and anti-rabbit antibodies (1/
50000 dilution, P0448, Dako) were used as secondary
antibodies for visualization with Supersignal West Dura
(Thermo Scientific).
BlaP enzymatic assay
A native protein extraction was performed as follows: 50
worms were collected from NGM plates with S-buffer and
washed 3 times. Worms were suspended in native protein
extraction buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM
EDTA, 1 mM β-mercaptoethanol +1 tablet of a protease
inhibitor cocktail for 50 ml buffer (04693116001, Roche
diagnostics), in MagNa Lyser Green Beads tubes (Roche).
All samples were homogenized (MagNa Lyser, Roche
using 3 cycles of 10s at 4800 rpm, samples were put on ice
for 5 min in between the cycles) and centrifuged for
20 min at 16000 g and 4 °C. Supernatant was transferred
to a new tube and kept at −80 °C until further use.
A qualitative enzymatic test was carried out to detect
the presence of functional BlaP in the worm extracts by
mixing 15 μL of the extract with 0.1 mM nitrocefin
solution in 50 mM phosphate buffer pH 7; in the presence
of functional BlaP nitrocefin turns red. For the
BlaP197Q72 strain, quantitative measurements were car-
ried out by measuring the initial rate of hydrolysis of
nitrocefin (95 μM in 50 mM phosphate buffer pH 7) re-
corded at 486 nm, for 120-180 min at 25 °C using a Tecan
plate reader Infinite 200. The initial rate of hydrolysis
(ΔA.min−1) is given by the slope of the graph representing
the absorbance as a function of time when less than 10%
of substrate is hydrolyzed. Initial rate of hydrolysis of
nitrocefin obtained with known concentrations of
BlaP197Q79 were also measured to draw standard curves
from which the concentration of functional BlaP197Q72
chimera in worm extracts could be derived. At least tripli-
cate measurements were carried out for each worm
extract and standard solutions, and at least two independ-
ent worm extracts were prepared. In order to ensure that
the enzyme was not degrading in the worm extract, pure
BlaP197Q79 was incubated in the worm extracts for
60 min and then the initial rate of hydrolysis of cephalo-
thin (90 μM in 50 mM phosphate buffer pH 7) was com-
pared to that of the same enzyme incubated at the same
concentration in phosphate buffer pH 7 for one hour.
Locomotion assay
Locomotion of transgenic animals was determined by
recording the average speed of different transgenic strains
using unseeded NGM plates (i.e. in absence of food).
Worms (n = 12-24) were recorded for 1 min using a
ToupCam (Touptek Photonics, China) equipped on an
M165 FC microscope (Leica, Germany). Movies were
inverted creating a white background/black worm
format for further analysis using the Parallel Worm
Tracker [43]. Statistical analysis was performed using
one-way ANOVA (Graphpad Prism 5, GraphPad
Software, USA). P values <0.05 were considered
significant.
Dot blot analysis
The relative expression levels of some BlaP-polyQ
chimeras and of Q82::YFP animals were confirmed by
dot blot. For this purpose, worm extracts were
prepared and collected as described before (Western
blot analysis).
2 μl of each sample was spotted on a nitrocellulose
membrane and the samples were allowed to dry for 1 h.
The membrane was then incubated at room temperature
(1) for 2 h in 5% blocking agent (GE Healthcare) and (2)
with primary mouse anti-polyQ antibody (1/1000 dilution
in Tris-Saline pH 7.6, 5TF1-1C2, Millipore) or primary
rabbit anti-Histone H3 antibody (1/20000 dilution in
Tris-Saline pH 7.6, ab8580, Abcam). Horse Radish
Peroxidase-conjugated rabbit anti-mouse (1/50000
dilution in Tris-Saline pH 7.6, P0161, Dako) or goat anti-
rabbit (1/50000 dilution in Tris Saline, pH 7.6, P0160,
Dako) were used as secondary antibodies for visualization
with Supersignal West Dura (Thermo Scientific).
Dot blot signals were analysed using ImageJ. Upon
removal of background signals, the polyQ signal was
normalized to the Histone H3 signal, which functioned
as an endogenous loading control.
Results
Qualitative analyses show that C. elegans expresses
BlaP-polyQ chimeras
Transgenic strains expressing BlaP197Q0/58/72 and
BlaP216Q0/55/79 in the body wall muscle cells, and
ubiquitously expressing BlaP216Q55/79, were
generated. The expression of BlaP-polyQ chimeras
under the control of either the Punc-54 muscle-spe-
cific promotor or the Prpl-28 ribosomal promotor
was confirmed using Western blot analysis (Fig. 2).
A band corresponding to the expected molecular
weight is observed in extracts of worms expressing
BlaP197Q58, BlaP197Q72, BlaP216Q55 or
BlaP216Q79. Wild type worms, as is to be expected,
do not express BlaP.
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The presence of functional chimeric proteins produced
in C. elegans was further demonstrated using the enzym-
atic activity of BlaP as readout (Fig. 3). The results
confirmed that indeed, the native forms of
BlaP197Q72 and BlaP216Q79 are present in our
transgenic strains (Fig. 3).
Expression of BlaP-polyQ does not affect C. elegans
locomotion or unfolded protein response
Toxic protein aggregation in the muscle cells of the
worm will lead to impaired locomotion [32, 44–46],
which provides a robust readout for polyQ proteo-
toxicity in an in vivo system. We evaluated overall
locomotion of the BlaP197-polyQ chimera strains on
days 1 and 3 of adulthood (Fig. 4). Unlike the slow
positive control (amyloid-β expression in C. elegans
body wall muscle cells is known to affect locomotion
[47]), transgenic BlaP197-polyQ chimera strains
display normal locomotion at these early days of
adulthood. As observed in previous research [48] and
being a result of aging, the overall speed of the
worms is lower at day 3 of adulthood as compared to
day 1 adult worms (Fig. 4).
Based on in vitro data [18], it is to be expected that
BlaP216-polyQ chimeras are more aggregation-prone
than their BlaP197-chimera counterparts. Therefore,
they may have a more pronounced impact on C. elegans
locomotion. The expression of BlaP216Q55 or
BlaP216Q79, be it ubiquitous or in the body wall muscle
cells, did however not result in an altered locomotion
phenotype (Fig. 5).
The positive control strain used in the above-
mentioned locomotion assays expresses Aβ42 in the
body wall muscle cells of C. elegans and exhibits a con-
sistent slow phenotype [23], ensuring proper execution
of the experiment. To prove that a similar observation
can indeed be used for estimating polyQ toxicity, a
Fig. 2 Verification of the expression of BlaP197- and BlaP216-polyQ chimeras using Western blot with a primary antibody against polyQ. a Transgenic
strains expressing BlaP197Q58 and BlaP197Q72 in body wall muscle (BWM) cells (Punc-54). b Transgenic strains expressing BlaP216Q55 and BlaP216Q79 in
the BWM cells, or (c) in all cells (Prpl-28). One μg pure BlaP197Q79 or BlaP216Q79 was added as a positive control and protein extracts from wild-type
worms function as a negative control
Fig. 3 a) Nitrocefin assay of transgenic strains expressing A) BlaP197Q0/
58/72 in the body wall muscle cells (BWM) and b) BlaP216Q0/55/79 in
body wall muscle cells or ubiquitously supports functional BlaP
expression. For each series, the first tubes represent the endogenous
colour of nitrocefin before BlaP hydrolysis. Next, a negative control
(extraction buffer), positive control (pure BlaP197Q79 and BlaP216Q79),
extracts from wild-type worms and the transgenic BlaP strains are shown.
Pictures were taken immediately after addition of the substrate, data are
qualitative and show that all strains express functional β lactamase
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strain expressing 82 Qs fused to the N-terminus of YFP
(Q82::YFP) in the body wall muscle cells of C. elegans
was also subjected to the assay (Fig. 6). This strain is
characterized by fast and strong protein aggregation
[32], demonstrating that the observed locomotion of
animals expressing aggregating polyQ proteins is indeed
altered to the same extent as that of worms expressing
Aβ (Fig. 6).
Since unfolded protein response (UPR) levels are
known to be elevated as a result of protein misfold-
ing/aggregation [49], a tunicamycin UPR stress assay
was conducted to serve as a potential alternative
readout. Unlike the positive control (xbp-1 mutant)
which is unable to induce an unfolded protein re-
sponse [50], Q82::YFP and transgenic BlaP-polyQ
strains show no increased mortality due to the
tunicamycin-induced UPR stress (Additional file 1:
Figure S2).
As locomotion-based results indicate the absence of
polyQ toxicity, hence of aggregates in our strains, we
also tried to visualize and quantify potential aggregates
by means of both a thioflavin stain and SDD-AGE
analyses (Additional file 1: Figure. S3-5). We however
faced technical limitations and rely on the indirect
readout of normal locomotion (Figs. 4, 5 and 6) to
suggest that BlaP-polyQ chimeras do not significantly
aggregate in our strains.
BlaP-polyQ expression levels in non-aggregating strains
are similar to polyQ expression in positive controls
While no clear functional readout could be observed, it
is still possible that some BlaP-polyQ chimeras aggregate
in these animals, yet not in sufficient amount to bring
about functional consequences. One obvious explanation
for the absence of significant aggregation or phenotypic
effects would be an insufficient level of transgenic
Fig. 4 Overall spontaneous speed of locomotion of transgenic BlaP197-polyQ chimera strains on (a) day 1 and (b) day 3 of adulthood is similar to wild type
speed. Wild type animals and a slowly moving amyloid-Aβ42 expressing strain serve as appropriate normal (negative) and slow (positive)
controls, respectively (n = 13-22 for each condition). The values obtained for the positive control strain are significantly different from
those obtained for the wild-type animals at both times [P values <0.001 (***)]. Error bars indicate standard error of the mean
Fig. 5 Overall locomotion of transgenic strains with (a) body wall muscle cells expression (b) and ubiquitous expression of BlaP216Qx on day 3 of
adulthood. Wild type animals and a slowly moving amyloid-β expressing strain serve as appropriate normal (negative) and slow (positive) controls
(n = 12-24 for each condition). The values obtained for the positive control strain are significantly different from those obtained for the wild-type
animals at both times [P values <0.001 (***) in (A) and <0.01 (**) in (B)]. Error bars indicate standard error of the mean
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protein expression. Based on sample availability, relative
and absolute expression levels for several strains were
evaluated using Western blot, dot blot and enzymatic ac-
tivity analyses.
The Western blot signal of BlaP-polyQ in the trans-
genic strains was compared to a dilution series of pure
BlaP-polyQ chimeras. Concentrations ranging around 20
to 60 μM were estimated inside a single worm, assuming
cylindrical adults of 1 mm in length and 40 μm in diam-
eter, and a homogenous distribution of the protein
throughout the animal (Fig. 7a). Using similar
assumptions, levels of the clearly aggregating Q82::YFP -
under control of the same body wall muscle cell pro-
moter as the BlaP216Q55/79 strains - were estimated to
be around 20 μM (Fig. 7b). This indicates that BlaP chi-
meras do not aggregate even though they are expressed
at similar concentrations as Q82::YFP in C. elegans.
We in addition relied on dot blot analyses (Fig. 8) of
some of these strains to compare the relative level of
expression of BlaP-polyQ chimeras to that of Q82::YFP.
The results obtained confirmed that the expression
levels of the BlaP-polyQ chimeras are comparable to that
of Q82::YFP.
Finally, we aimed to confirm expression estimates via
enzymatic activity measurements. Pure BlaP197Q79 was
used to establish a standard curve from which the
concentration of the protein in the worms could be de-
rived (Table 2). In line with expectations and under the
same approximations of cylindrical worm volume and
homogenous protein distribution, this methodology esti-
mated BlaP197Q72 concentration to be 33.9 ± 6.2 μM in
the worm. This confirmed that functional expression
levels of this chimera are within the same range as the
total concentrations calculated above (Fig. 7).
Seeding polyQ aggregation does not induce aggregation
of BlaP197Q72
Since no clear phenotypic defect or protein aggregation
were observed in the BlaP transgenic strains, it can be
asked whether the timescale needed for in vivo aggrega-
tion might be drastically longer than that of the in vitro
process. In order to speed up the in vivo aggregation of
the BlaP chimeras in our model system, a seeding assay
was performed. By expressing BlaP197Q72, of which the
concentrations were in the expected order of magnitude,
Fig. 6 Positive control strains expressing either Aβ- or Q82:YFP display
similar reductions in locomotion as compared to wild-type animals. Data
collected on day 3 of adulthood. (n = 9-13 for each condition). Transgenic
strains expressing either Aβ or Q82::YFP displayed a significant locomotion
defect (both P values <0.001 (***)). Error bars indicate standard error of
the mean. BMW: body wall muscle cells specific expression
Fig. 7 Expression levels of (a) BlaP-polyQ chimeras and (b) 82Q::YFP in transgenic strains expressing BlaP216Q55/79 and Q82::YFP in the body wall
muscle cells. Twofold dilution series of pure BlaP197Q79 and YFP were analyzed in order to estimate transgenic expression levels using Western
blot (mouse anti-polyQ antibody, 5TF1-1C2, Millipore). Additional bands in the (B) dilution series are observed, representing dimers of pure YFP.
The Q82::YFP signal is observed at 38 kDa due to the additional weight of the polyQ region. Vertical lines were added to the image to aid in lane
discrimination of the single immunoblot represented in the figure
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in a pro-aggregating genetic background, facilitated
aggregation can be expected [20]. The AM140 strain
expresses a Q35 region fused to YFP in its body wall
muscle cells. Aggregation can be inferred from the
appearance of fluorescent spots in these cells, replacing
the normal, diffuse YFP signal [32]. By expressing the
aggregation-prone BlaP197Q72 chimera in this
background, a faster aggregation process might be
expected. However, we did not observe such accelerated
aggregation for BlaP197Q72 (Fig. 9).
Discussion
Protein aggregation is associated with several neurode-
generative disorders [51–54]. An impaired protein
homeostasis greatly impacts the aggregation process, but
the mechanisms behind this principle have not yet been
fully elucidated [55]. Because numerous biochemical
events influence protein homeostasis, in vivo analysis of
protein aggregation is indispensable to investigate
potential toxic effects of in vitro aggregation-prone pro-
teins and to investigate how much these latter depend
on the nature of the protein that aggregates within an in
vivo context.
Different in vitro aggregation-prone BlaP197- and
BlaP216-polyQ chimeras were functionally expressed in
the body wall muscle cells of C. elegans (Figs. 2 and 3), a
tissue chosen because of its easy phenotypic readout
upon toxic protein aggregation [32, 35, 56, 57]. In
addition, the theoretically more toxic BlaP216Q79
chimeras were also expressed ubiquitously, an interven-
tion that should generate a most severe phenotype.
However, we never observed any clear aberrant locomo-
tion phenotype, despite proper expression of the BlaP--
polyQ chimeras in all strains and the clear presence of
enzymatic activity (Figs. 2, 3, 4, 5 and 6). This suggests
that aggregation of BlaP chimeras may not be taking
place in these models.
In vitro aggregation studies show that under native
conditions (i.e. in 50 Mm phosphate buffer, 150
mMNaCl, pH 7 at 25 or 37°c and protein concentration
of 40 μM) BlaP197Q79, BlaP216Q55 and BlaP216Q79
readily form fibrillar aggregates [6, 17, 18, 58]. Because
the transgenic strains expressing these proteins do not
Fig. 8 Relative PolyQ protein levels as determined by dot blot analysis. Total polyQ protein levels of transgenic strains expressing BlaP197Q0,
BlaP197Q58 and BlaP197Q72 in body wall muscle (BWM) cells (Punc-54), or ubiquitously expressed BlaP216Q55 and BlaP216Q79 (Prpl-28) were
determined by dot blot analysis using an anti-polyQ antibody. Pure BlaP197Q79 or BlaP216Q79, as well as a transgenic strain expressing Q82::YFP
in BWM were added as positive controls; protein extracts from wild-type worms function as a negative control. The signal was analysed using
ImageJ. After background removal, the polyQ signal was normalized to the histone H3 signal. Each bar represents an individual biologically
independent sample. The average of both wild type values was set to 1
Table 2 Enzymatic activity measurements
Sample Volume Initial rate of
Hydrolysis (ΔA/min)
[BlaP197Q79] in the extract (nM) Average [BlaP197Q79]
in the extract (nM)
Average concentration in
50 worms (~0.063 μL)
Replicate 1 2 3 1 2 3
BlaP197Q72 extract 1 330 μL 0.0056 0.0053 0.0056 5.71 5.46 5.73 5.63 ± 0.15 29.5 ± 0.8 μM
BlaP197Q72 extract 2 365 μL 0.0071 0.0062 0.0061 7.26 6.30 6.21 6.59 ± 0.58 38.2 ± 3.4 μM
The initial hydrolysis rate of nitrocefin is given by ΔA.min−1, the slope of the graph representing the absorbance as a function of time when less than 10% of
substrate is hydrolysed
Based on the enzymatic activity measurements and assumptions detailed in the main text, an average concentration of 33.9 ± 6.2 μM BlaP197Q79 could
be calculated
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show significant aggregate formation, it can be asked
how C. elegans copes with these otherwise aggregation-
prone entities. Such questions have also been raised in
other organisms. C. albicans seems to exhibit mecha-
nisms allowing this organism to properly cope with
polyQ aggregates without causing any toxic effects [59].
Whereas C. elegans data are yet inconclusive, this worm
also seems to cope better with several stress-inducing
factors, suggesting a more effective proteostasis.
Additionally, Brignull et al. indicated that in C. elegans,
protein quality control mechanisms and capacity can
vary widely among neurons implying discrepancies
depending on the cells used to model protein aggrega-
tion [41]. Additionally, an asymmetric inheritance of
damaged proteins is observed in Drosophila melanoga-
ster, Escherichia coli, Saccharomyces cerevisiae and
mouse or human stem cells. As such, daughter cells tend
to be more protected from toxic effects of damaged
proteins. For example, stem cells expressing polyQ ag-
gregates of ataxin-3 are believed to employ a specific
mechanism to remove damaged proteins, which would
explain the absence of large aggregates in these cells
[60–62]. Moreover, according to the supersaturation
hypothesis of aggregation-prone proteins [63], the level
of expression is crucial. In vitro aggregation kinetics of
BlaP-polyQ chimeras have been described using
relatively high concentrations of BlaP (≥ 40 μM,
Scarafone et al. 2012; unpublished results). The esti-
mated amount of BlaP expressed in C. elegans is never-
theless somewhat in that range as shown by Western
blot, dot-blot (Figs. 7 and 8) and activity measurements
(Table 2). It should be noted that our non-integrated
transgenic C. elegans strains, as can be expected, are
characterized by a range of transgene expression levels,
somewhat impeding highly controlled experiments.
Since - even when taking such variation into account -
these levels of expression are also similar to those
detected in well-established aggregating polyQ strains
(Figs. 7.b and 8), the aggregating propensities of BlaP are
probably too low to cause a defined in vivo effect.
In contrast to in vitro studies, protein quality control
processes provided by chaperones, ubiquitin-proteasome
and autophagy-lysosome degradation systems all act
against the aggregation process in vivo. Although one
might assume that the UPR is elevated in the transgenic
strains due to the expression of different BlaP-polyQ
chimera proteins, no increased sensitivity to UPR stress
was observed in the tunicamycin UPR stress assay
(Additional file 1: Figure S2). C. elegans might cope in a
different way with overexpression of potentially toxic
proteins since Q82::YFP expression did also not result in
an increased sensitivity to UPR stress.
The conformational state of the BlaP moiety influences
the formation and elongation of amyloid fibrils in vitro
[18] and fibril formation of some BlaP-polyQ chimeras
takes only a few hours in vitro [6]. Therefore, next to
the in vivo context mentioned above, the fact that the
polyQ region is embedded within a host protein likely
affects the in vivo aggregation properties of these chi-
meras as well. This might explain why aggregation can
be observed in case of a polyQ::YFP chimera bearing a
similar number of Qs (i.e. 82 versus 72/79 for BlaP
chimeras) [32, 41], where the fusion is at YFP’s
N-terminus, but not in case of the different BlaP-polyQ
chimeras, where the polyQ is embedded within the
sequence. Embedded polyQ regions have successfully led
to aggregation in C. elegans before, however, some of
these contained longer polyQ regions (74 Q – 150 Q)
longer. In this scenario, this would either mean that
aggregation of embedded polyQ requires higher thresh-
olds than terminal polyQ, or that the individual protein
context, rather than a general terminal vs. embedded
polyQ position might matter. These hypotheses could be
verified in follow-up research including N-terminal
BlaP-polyQ chimeras, as well as embedded polyQ with
longer repeat length.
Sequences immediately adjacent to the polyQ region
have shown to be of significant importance for in vivo
aggregation (e.g. [40]). Additionally, the ability to modify
or interact with these amino acids has been shown to
Fig. 9 Expression of BlaP197Q72 in a pro-aggregating Q35::YFP background does not result in a faster aggregation process. Expression of BlaP197Q72
in a pro-aggregating Q35::YFP background was established and every 12 h - starting from the L1 stage and until adulthood - the aggregation pattern
was visualized. The upper panels represent the transgenic strain expressing BlaP197Q72 in a pro-aggregating Q35::YFP background, the lower panels
represent the transgenic Q35::YFP strain as a control. Scale bar represents 0.1 mm
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contribute as well: sumoylation facilitates polyQ toxicity
in mammalian cells [64]. Mimicking this, research in yeast
has shown that pseudosumoylation can be achieved by
adding an acidic FLAG-tag [65, 66]. In yet another
example of the importance of the flanking region, the ab-
sence of proline-rich sequences adjacent to the polyQ re-
gion seems to unmask toxicity in yeast as their presence
targets the protein to the aggresome [65, 67]. Interestingly,
these flanking sequences have not only shown to have
cis-regulatory effects, trans effects have been observed as
well [66]. Similar observations have been made in C. ele-
gans research. Here, interactions between polyQ regions
with the mutant ataxin-3 protein-flanking sequences are
believed to be crucial for forming aggregates [68]. To-
gether, these findings show that flanking sequences are
paramount for polyQ toxicity and aggregation, which
could – be it partially or wholly – explain the absence of
toxicity of the BlaP-polyQ strains investigated here. One
way to address this in the future, would be to express BlaP
chimeras with extremely long polyQ repeats (>150 Q),
which theoretically might annul the assumedly benefits of
the flanking regions regarding solubility and aggregation.
Additionally, C. elegans is characterized by a relatively
short lifespan. Since the aggregation process of soluble
proteins into highly organized amyloid fibrils has been
described as a nucleation-dependent polymerization
mechanism, it could be that the aggregation process of
BlaP-polyQ chimeric proteins takes too long to cause
distinct effects in C. elegans. This touches upon a more
general question regarding the compressibility of ageing
in absolute time, and hence of proper modelling of the
associated phenotypes in short-living model organisms.
Notwithstanding this, C. elegans has already proven to
be a good model in the study of other aggregation-prone
proteins such as amyloid-β or α-synuclein [69–71]. Still,
for potentially less toxic proteins this model system
might simply be too short-living. Comparative in vivo
toxicity studies of these proteins could be conducted in
model organisms with a longer lifespan, granting the
proteins more time to aggregate. Such studies will de-
mand more time and will probably entail more variation.
In an attempt to compensate for the shorter timescale of
observation as a consequence of C. elegans lifespan, we
expressed BlaP197Q72 in a pro-aggregating background,
hoping to facilitate the slower nucleation events of amyl-
oid fibril formation [20]. However, also in these animals
no aggregation was observed (Fig. 9).
Finally, intracellular conditions (such as pH,
temperature and crowding) differ significantly from
those used in in vitro studies (i.e. in vitro aggregation
studies are carried out in 50 mM phosphate buffer
pH 7.5 containing 150 mM NaCl at 37 °C while in
vivo experiments occur in a complex cellular
environment at 20 °C). Adjustment of these
parameters strongly influences the aggregation pro-
pensities of the proteins [6, 18]. By relying on an in
vivo model, the ability to alter these parameters is
limited by cellular and organismal requirements.
Although this confers biological significance, it could
also impede the aggregation in our models.
Prospects for BlaP-polyQ chimera aggregation studies in
C. elegans
C. elegans has a good track record as model in the study
of protein aggregation [41, 69, 71, 72]. This study shows
that C. elegans’ merits may serve certain studies, but not
others, depending on protein identity and context. The
inherent toxicity of the studied BlaP-polyQ proteins
within this worm’s in vivo context is probably too low to
lead to a distinct phenotype. Additionally, all strains
used in our experiments were transgenic. Hence, site-
specific integration of the transgene in the genome
would be desirable since this will reduce the expected
variation of the readout drastically. In this way, the copy
number and place of integration in the genome can be
controlled allowing for a better comparison between the
different strains. Bearing in mind that we injected the ani-
mals with high concentrations of transgenic target DNA
(70 ng/μl), expressed under robust, strong promoters, such
site-specific integration of the transgene would likely not
enhance aggregation, despite reducing interanimal vari-
ation. BlaP chimeras with more aggressive aggregation
properties, as discussed above, may still lead to distinct ef-
fects, and could therefore benefit from the elaborate C. ele-
gans toolbox in their initial in vivo evaluation. One other
way to model BlaP-polyQ in C. elegans, would be by ex-
pressing these proteins in an autophagy-defective back-
ground [73], potentially even aggravated by crossing such
strains with aggregation-prone backgrounds for seeding.
This could yet allow for valuable comparative, highly con-
trollable in vivo studies if interpreted cautiously.
Conclusion
We have generated a series of transgenic strains expressing
BlaP-polyQ proteins bearing polyQ regions of different
lengths embedded within two different locations in the BlaP
sequence. Despite the verification of proper functional ex-
pression at relevant levels of the different proteins, no clear
phenotypic consequences were observed. Furthermore, ex-
pressing BlaP197Q72 in a pro-aggregating background did
not result in accelerated aggregation kinetics. The absence
of a toxic in vivo effect is likely a result of several causes.
Since C. elegans has a relatively short lifespan, the time
needed to build up significant aggregation may surpass the
worm’s lifespan. Functional protein quality control pro-
cesses and the differences between in vivo biochemical con-
ditions (such as pH or temperature) and in vitro studies
likely all contribute to the observed resistance to toxic
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aggregation. These observations emphasize the need for
proper in vivo evaluation and choice of multiple model sys-
tems for comparative purposes and validation of biochem-
ical findings.
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